BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Nov 24, 2026; 17(11): 127405
Published online Nov 24, 2026. doi: 10.5306/wjco.127405
Three S’s (sex, seniors, and sarcopenia) matter during chemotherapy for colorectal cancer
Hiroaki Nozawa, Koji Murono, Shigenobu Emoto, Soichiro Ishihara
Hiroaki Nozawa, Koji Murono, Shigenobu Emoto, Soichiro Ishihara, Department of Surgical Oncology, The University of Tokyo, Tokyo 113-8655, Japan
Author contributions: Nozawa H conceptualized the study, conducted the literature search and review, interpretation of data, drafted the original manuscript and created the artwork; Murono K and Emoto S made critical revisions; Ishihara S supervised, and made critical revisions; all authors approved the submitted version.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement. The authors carefully reviewed and verified all AI-assisted outputs and take full responsibility for the scientific content of the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest.
Corresponding author: Hiroaki Nozawa, MD, PhD, Associate Professor, Department of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. hiroanozawa@yahoo.co.jp
Received: August 31, 2026
Revised: September 20, 2026
Accepted: October 16, 2026
Published online: November 24, 2026
Processing time: 81 Days and 1.4 Hours
Abstract

Recent progress in treatments has dramatically improved the outcomes of colorectal cancer (CRC). Neoadjuvant chemoradiotherapy (CRT) has been the standard therapy for resectable advanced cancer of the lower rectum, and the combination of additional systemic chemotherapy before or after CRT is attracting attention for further improvement of local antitumor effects. Patients with unresectable CRC have a good chance of conversion to resection after the use of key cytotoxic drugs, such as 5-fluorouracil, oxaliplatin, and irinotecan, along with targeted antibodies. Furthermore, immune checkpoint inhibitors are available in these neoadjuvant settings. For adjuvant chemotherapy of localized CRC, the recommended treatment is 5-fluorouracil plus oxaliplatin. Meanwhile, accumulating evidence shows that sarcopenia is associated with adherence to and outcomes of these treatments. For instance, sarcopenia or skeletal muscle loss occurring before and during preoperative treatments predict poor prognosis in patients undergoing neoadjuvant CRT and those who received conversion therapy for unresectable CRC. Sarcopenia or skeletal muscle loss is also associated with dose-limiting toxicity and the outcomes of adjuvant chemotherapy. Importantly, unchangeable variables such as age and sex often determine sarcopenia and/or chemotherapy tolerability. This review describes the clinical significance of the three S’s (sex, seniors, and sarcopenia) in chemotherapy/CRT used in various settings for CRC.

Keywords: Colorectal cancer; Chemotherapy; Chemoradiotherapy; Sex; Seniors; Sarcopenia

Core Tip: The majority of patients with colorectal cancer (CRC) undergo chemotherapy and/or chemoradiotherapy (CRT) in various settings. The safety and efficacy of these treatments may be affected by factors such as sex, age, and body compositions. Furthermore, these factors may be interrelated in the context of chemotherapy and CRT. It is crucial to understand the impact of the three S's (sex, seniors, and sarcopenia) on CRC treatment in clinical practice.

Write to the Help Desk